

**Listing of Claims:**

Claim 1 (previously cancelled)

Claim 2 (previously cancelled)

Claim 3 (previously cancelled)

Claim 4 (previously cancelled)

Claim 5 (previously cancelled)

Claim 6 (previously cancelled)

Claim 7 (previously cancelled)

Claim 8 (previously amended): A modified recombinant allergen wherein at least one of the T-cell reactive regions 16-42, 135-149 and 180-206 of the Phl p 5b polypeptide of SEQ ID NO: 87, consisting of a total of 265 amino acids, is not altered.

Claim 9 (previously amended): A modified recombinant allergen according to claim 8, selected from the group consisting of:

PM1	(N <sup>32</sup> → D, D <sup>49</sup> → L, K <sup>50</sup> → A)	(SEQ ID NO. 88)
PM2	(D <sup>49</sup> → L, K <sup>50</sup> → A)	(SEQ ID NO. 89)
PM3	(A <sup>13</sup> → C)	(SEQ ID NO. 90)
DM1	(Δ K <sup>50</sup> → P <sup>Δ132</sup> , D <sup>49</sup> → L)	(SEQ ID NO. 91)
DM2	(Δ F <sup>51</sup> - G <sup>178</sup> , D <sup>49</sup> - L, K <sup>50</sup> - A)	(SEQ ID NO. 92) and
DM3	(Δ A <sup>154</sup> - T <sup>177</sup> , A <sup>220</sup> → T)	(SEQ ID NO. 93).

§Appl. No. 09/381,903  
Amdt. dated December 24, 2003  
Reply to Office Action of July 1, 2003

Claim 10 (withdrawn).

Claim 11 (previously amended): A pharmaceutical preparation for treating an IgE-mediated allergy comprising at least one modified recombinant allergen according to claim 8 and a pharmaceutically acceptable carrier.

Claim 12 (withdrawn).

Claim 13 (currently amended) A method of immunospecific therapy (~~hypo~~sensitization) of allergies, comprising administering to a patient in need thereof a pharmaceutical composition comprising a modified recombinant allergen according to claim ~~4~~ 8 and a pharmaceutically acceptable carrier.

Claim 14 (currently amended) A method of immunospecific therapy (~~hypo~~sensitization) of allergies, comprising administering to a patient in need thereof a modified recombinant allergen according to claim ~~4~~ 8.

Claim 15 (previously added): The pharmaceutical preparation according to claim 11 comprising a physiologically compatible salt or solvate of said recombinant modified allergen.

§Appl. No. 09/381,903  
Amdt. dated December 24, 2003  
Reply to Office Action of July 1, 2003

Claim 16 (previously added): The pharmaceutical preparation according to claim 11 comprising an additional active compound.

Claim 17 (previously amended): A modified recombinant allergen having a region which corresponds to at least one of the T-cell reactive regions 16-42, 135-149, and 180-206 of the Ph1 p 5b polypeptide of SEQ ID NO: 87, consisting of a total of 265 amino acids, wherein at least one of said regions is not altered.

Claim 18 (previously added): A modified recombinant allergen of claim 17, wherein a combination of said regions is present and is not altered.

Claim 19 (previously amended): A modified recombinant allergen according to claim 17, selected from the group consisting of:

PM1	(N <sup>32</sup> → D, D <sup>49</sup> → L, K <sup>50</sup> → A)	(SEQ ID NO. 88)
PM2	(D <sup>49</sup> → L, K <sup>50</sup> → A)	(SEQ ID NO. 89)
DM1	(Δ K <sup>50</sup> → P <sup>Δ132</sup> , D <sup>49</sup> → L)	(SEQ ID NO. 91) <del>or</del> <u>and</u>
DM3	(Δ A <sup>154</sup> - T <sup>177</sup> , A <sup>220</sup> → T)	(SEQ ID NO. 93).

Claim 20 (previously amended): The modified recombinant allergen according to claim 8, wherein said modification refers to a wild type polypeptide that is altered by a substitution.

§Appl. No. 09/381,903  
Amdt. dated December 24, 2003  
Reply to Office Action of July 1, 2003

Claim 21 (previously amended): The modified recombinant allergen according to claim 17, wherein said modification refers to a wild type polypeptide that is altered by a deletion.

Claim 22 (previously added): An allergen of claim 8, wherein a combination of said regions is present and is not altered.

Claim 23 (withdrawn):

Claim 24 (newly added) A method of immunospecific therapy of allergies, comprising administering to a patient in need thereof a modified recombinant allergen according to claim 9 which is DM1 or DM3.

Claim 25 (newly added) A method of immunospecific therapy of allergies, comprising administering to a patient in need thereof a modified recombinant allergen according to claim 17.

Claim 26 (newly added) A method of immunospecific therapy of allergies, comprising administering to a patient in need thereof a modified recombinant allergen according to claim 19 which is PM1 or PM2

Claim 27 (newly added) A method of immunospecific therapy of allergies, comprising

§Appl. No. 09/381,903  
Amdt. dated December 24, 2003  
Reply to Office Action of July 1, 2003

administering to a patient in need thereof a modified recombinant allergen according to claim 20.

Claim 28 (newly added) A method of immunospecific therapy of allergies, comprising  
administering to a patient in need thereof a modified recombinant allergen according to claim 21.

Claim 29 (newly added) A method of immunospecific therapy of allergies, comprising  
administering to a patient in need thereof a modified recombinant allergen according to claim 22.